These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 25125467)

  • 1. Serum MHPG strongly predicts conversion to Alzheimer's disease in behaviorally characterized subjects with Down syndrome.
    Dekker AD; Coppus AM; Vermeiren Y; Aerts T; van Duijn CM; Kremer BP; Naudé PJ; Van Dam D; De Deyn PP
    J Alzheimers Dis; 2015; 43(3):871-91. PubMed ID: 25125467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum NGAL is Associated with Distinct Plasma Amyloid-β Peptides According to the Clinical Diagnosis of Dementia in Down Syndrome.
    Naudé PJ; Dekker AD; Coppus AM; Vermeiren Y; Eisel UL; van Duijn CM; Van Dam D; De Deyn PP
    J Alzheimers Dis; 2015; 45(3):733-43. PubMed ID: 25613101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease.
    Aerts MB; Esselink RA; Claassen JA; Abdo WF; Bloem BR; Verbeek MM
    J Alzheimers Dis; 2011; 27(2):377-84. PubMed ID: 21841257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia.
    Engelborghs S; Vloeberghs E; Le Bastard N; Van Buggenhout M; Mariën P; Somers N; Nagels G; Pickut BA; De Deyn PP
    Neurochem Int; 2008 May; 52(6):1052-60. PubMed ID: 18093695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease.
    Dekker AD; Vermeiren Y; Carmona-Iragui M; Benejam B; Videla L; Gelpi E; Aerts T; Van Dam D; Fernández S; Lleó A; Videla S; Sieben A; Martin JJ; ; Blesa R; Fortea J; De Deyn PP
    Alzheimers Dement (Amst); 2018; 10():99-111. PubMed ID: 29780859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma β amyloid and the risk of Alzheimer's disease in Down syndrome.
    Coppus AM; Schuur M; Vergeer J; Janssens AC; Oostra BA; Verbeek MM; van Duijn CM
    Neurobiol Aging; 2012 Sep; 33(9):1988-94. PubMed ID: 21958962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ascending monoaminergic systems alterations in Alzheimer's disease. translating basic science into clinical care.
    Trillo L; Das D; Hsieh W; Medina B; Moghadam S; Lin B; Dang V; Sanchez MM; De Miguel Z; Ashford JW; Salehi A
    Neurosci Biobehav Rev; 2013 Sep; 37(8):1363-79. PubMed ID: 23707776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total serum cholesterol levels and Alzheimer's dementia in patients with Down syndrome.
    Prasher VP; Airuehia E; Patel A; Haque MS
    Int J Geriatr Psychiatry; 2008 Sep; 23(9):937-42. PubMed ID: 18395888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain region-specific monoaminergic correlates of neuropsychiatric symptoms in Alzheimer's disease.
    Vermeiren Y; Van Dam D; Aerts T; Engelborghs S; De Deyn PP
    J Alzheimers Dis; 2014; 41(3):819-33. PubMed ID: 24685637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome.
    Schupf N; Patel B; Silverman W; Zigman WB; Zhong N; Tycko B; Mehta PD; Mayeux R
    Neurosci Lett; 2001 Apr; 301(3):199-203. PubMed ID: 11257432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease.
    Vermeiren Y; Van Dam D; Aerts T; Engelborghs S; Martin JJ; De Deyn PP
    Alzheimers Res Ther; 2015; 7(1):7. PubMed ID: 25717350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome.
    Hamlett ED; Goetzl EJ; Ledreux A; Vasilevko V; Boger HA; LaRosa A; Clark D; Carroll SL; Carmona-Iragui M; Fortea J; Mufson EJ; Sabbagh M; Mohammed AH; Hartley D; Doran E; Lott IT; Granholm AC
    Alzheimers Dement; 2017 May; 13(5):541-549. PubMed ID: 27755974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral correlates of cerebrospinal fluid amino acid and biogenic amine neurotransmitter alterations in dementia.
    Vermeiren Y; Le Bastard N; Van Hemelrijck A; Drinkenburg WH; Engelborghs S; De Deyn PP
    Alzheimers Dement; 2013 Sep; 9(5):488-98. PubMed ID: 23159046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of plasma Aβ as predictor of Alzheimer's disease in older individuals without dementia: a population-based study.
    Hansson O; Stomrud E; Vanmechelen E; Östling S; Gustafson DR; Zetterberg H; Blennow K; Skoog I
    J Alzheimers Dis; 2012; 28(1):231-8. PubMed ID: 21955816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioural and psychological symptoms of dementia in Down syndrome: Early indicators of clinical Alzheimer's disease?
    Dekker AD; Strydom A; Coppus AM; Nizetic D; Vermeiren Y; Naudé PJ; Van Dam D; Potier MC; Fortea J; De Deyn PP
    Cortex; 2015 Dec; 73():36-61. PubMed ID: 26343344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome.
    Prasher VP; Sajith SG; Mehta P; Zigman WB; Schupf N
    Int J Geriatr Psychiatry; 2010 Feb; 25(2):202-7. PubMed ID: 19513990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome.
    Head E; Doran E; Nistor M; Hill M; Schmitt FA; Haier RJ; Lott IT
    J Alzheimers Dis; 2011; 23(3):399-409. PubMed ID: 21116050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome.
    Schupf N; Patel B; Pang D; Zigman WB; Silverman W; Mehta PD; Mayeux R
    Arch Neurol; 2007 Jul; 64(7):1007-13. PubMed ID: 17620492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: Comprehensive Assessment of Psychopathology in Down Syndrome.
    Dekker AD; Sacco S; Carfi A; Benejam B; Vermeiren Y; Beugelsdijk G; Schippers M; Hassefras L; Eleveld J; Grefelman S; Fopma R; Bomer-Veenboer M; Boti M; Oosterling GDE; Scholten E; Tollenaere M; Checkley L; Strydom A; Van Goethem G; Onder G; Blesa R; Zu Eulenburg C; Coppus AMW; Rebillat AS; Fortea J; De Deyn PP
    J Alzheimers Dis; 2018; 63(2):797-819. PubMed ID: 29689719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.